Pfizer Announces Topline Phase 3 Results For Sigvotatug Vedotin In Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer - R

· Sigvotatug Vedotin Does Not Improve Overall Survival Versus Docetaxel In Phase 3 Study · Sigvotatug Vedotin Shows Manageable Safety Profile Consistent With Prior Studies · No Clear IB6 Expression-Response Relationship Observed In Exploratory Analysis · Stronger Trend For OS And PFS With Sigvotatug Vedotin In Second-Line NSCLC Patients